PPARG and urinary bladder neoplasm: Likely as a consequence of the suppressive immuno-environment, we further demonstrate that PPARγ/RXRα pathway activity in the syngeneic bladder tumor model renders partial resistance to immune checkpoint blockade suggesting the potential for PPARγ/RXRα signaling to promote innate/acquired resistance to immunotherapies in the clinic.